J4T Stock Overview
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Onconetix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$0.41 |
| 52 Week Low | US$0.40 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -0.84% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| J4T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 2.5% |
| 1Y | n/a | -21.2% | 5.4% |
Return vs Industry: Insufficient data to determine how J4T performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how J4T performed against the German Market.
Price Volatility
| J4T volatility | |
|---|---|
| J4T Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: J4T has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine J4T's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Neil Campbell | onconetix.gcs-web.com |
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others.
Onconetix, Inc. Fundamentals Summary
| J4T fundamental statistics | |
|---|---|
| Market cap | €2.93m |
| Earnings (TTM) | -€16.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs J4T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J4T income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.28m |
| Earnings | -US$18.28m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 126.2% |
How did J4T perform over the long term?
See historical performance and comparison